Dashboard
1
With a growth in Net Profit of 806.69%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 241.18 MM
- PRE-TAX PROFIT(Q) At CNY 46.68 MM has Grown at 279.07%
- NET PROFIT(Q) At CNY 38.16 MM has Grown at 788.3%
2
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,624 Million (Mid Cap)
63.00
NA
0.70%
0.06
14.52%
6.71
Revenue and Profits:
Net Sales:
200 Million
(Quarterly Results - Jun 2026)
Net Profit:
46 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.4%
0%
1.4%
6 Months
39.49%
0%
39.49%
1 Year
85.84%
0%
85.84%
2 Years
133.57%
0%
133.57%
3 Years
23.33%
0%
23.33%
4 Years
-34.39%
0%
-34.39%
5 Years
-72.56%
0%
-72.56%
Shanghai Aladdin Biochemical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
23.02%
EBIT Growth (5y)
14.11%
EBIT to Interest (avg)
63.87
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.35
Tax Ratio
12.51%
Dividend Payout Ratio
45.16%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.50%
ROE (avg)
9.56%
Valuation key factors
Factor
Value
P/E Ratio
63
Industry P/E
Price to Book Value
9.13
EV to EBIT
50.39
EV to EBITDA
42.63
EV to Capital Employed
8.68
EV to Sales
12.39
PEG Ratio
5.34
Dividend Yield
0.26%
ROCE (Latest)
17.22%
ROE (Latest)
14.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
200.40
143.20
39.94%
Operating Profit (PBDIT) excl Other Income
60.60
33.70
79.82%
Interest
0.00
12.80
-100.00%
Exceptional Items
0.70
-0.00
Consolidate Net Profit
46.40
9.10
409.89%
Operating Profit Margin (Excl OI)
236.90%
169.00%
6.79%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 39.94% vs 2.29% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 409.89% vs -74.72% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
690.40
529.70
30.34%
Operating Profit (PBDIT) excl Other Income
214.80
170.30
26.13%
Interest
28.20
8.40
235.71%
Exceptional Items
-2.90
0.40
-825.00%
Consolidate Net Profit
135.10
115.70
16.77%
Operating Profit Margin (Excl OI)
250.00%
242.20%
0.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 30.34% vs 31.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 16.77% vs 34.85% in Dec 2024
About Shanghai Aladdin Biochemical Technology Co., Ltd. 
Shanghai Aladdin Biochemical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






